查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2056488

肺炎鏈球菌疫苗市場規模、佔有率、趨勢和預測：按疫苗類型、產品類型、分銷管道、最終用戶和地區分類，2026-2034 年

Pneumococcal Vaccine Market Size, Share, Trends and Forecast by Vaccine Type, Product Type, Distribution Channel, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年全球肺炎鏈球菌疫苗市場規模為102.6億美元，預計到2034年將達到155.1億美元，2026年至2034年預測期間的複合年成長率（CAGR）為4.30%。人口老化加劇、政府免疫計劃的擴大、肺炎鏈球菌感染負擔加重以及新一代結合疫苗平台的穩定發展，是推動肺炎球菌疫苗市場成長的主要因素。 2025年，肺炎鏈球菌結合疫苗將佔據市場主導地位，市佔率高達71.6%，其中Prevnar 13疫苗就佔全球產品需求的48.7%。北美地區預計將引領市場，佔全球銷售額的41.8%。

肺炎鏈球菌疫苗市場成長要素：

醫療保健成本不斷上漲

醫療保健支出的增加將使政府和私人醫療保健部門能夠擴大對免疫接種計畫的投資，從而提高肺炎球菌疫苗的可近性和成本效益，並最終提高人群的免疫接種率。因此，醫療保健支出的增加通常會帶來更完善的醫療保健基礎設施，包括免疫接種診所、分發網路和訓練有素的醫護人員。這些基礎設施支持肺炎球菌疫苗的管理和分發，從而促進市場成長。此外，醫療支出的增加也將促使製藥公司加強研發投入，加速開發覆蓋更多血清型或所需劑量更少的更有效的肺炎球菌疫苗。根據美國醫療保險和醫療補助服務中心 (CMS) 網站 2024 年更新的信息，醫療保健支出佔 GDP 的比例預計將從 2022 年的 17.3% 成長到 2032 年的 19.7%。

人口老化的過程

由於免疫力減弱和潛在健康問題，老年人更容易感染肺炎鏈球菌感染，包括肺炎和侵襲性肺炎鏈球菌感染。這種易感性促使人們擴大肺炎鏈球菌疫苗的使用，以預防嚴重。此外，許多政府和衛生機構建議將老年人接種肺炎球菌疫苗納入常規免疫計劃，這鼓勵醫護人員和老年人優先考慮接種疫苗，並推動了對肺炎球菌疫苗的需求。同時，衛生部門也優先考慮預防醫學策略，以改善老年人的健康狀況並最大限度地減少住院治療。世界衛生組織（世衛組織）網站上發表的報導預測，到2050年，全球整體60歲及以上人口數量預計將加倍，達到近21億。

膿毒症盛行率增加

根據世界衛生組織（世衛組織）網站2024年更新的信息，全球估計有近2000萬例敗血症病例發生在五歲以下兒童。肺炎鏈球菌是引起肺炎鏈球菌感染肺炎鏈球菌感染的細菌，也是敗血症的主要原因，尤其是免疫力的兒童。肺炎鏈球菌感染導致的敗血症發生率不斷上升，凸顯了疫苗接種等預防措施的重要性。此外，接種肺炎鏈球菌感染疫苗可顯著降低肺炎鏈球菌感染的風險，包括那些可能導致敗血症的感染。透過預防肺炎鏈球菌感染，疫苗有助於減輕醫療機構中敗血症的整體負擔。此外，將肺炎球菌疫苗作為預防敗血症的措施，也推動了銷售量的成長。透過在全球公共衛生干預措施中接種疫苗來預防敗血症的發病率和死亡率，正在支撐市場成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球肺炎鏈球菌疫苗市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依疫苗類型分類

  • 肺炎鏈球菌結合疫苗
  • 肺炎鏈球菌多醣體疫苗

第7章 市場區隔：依產品類型分類

  • 普雷布納 13
  • 辛弗洛里克斯
  • Pneumovax 23

第8章 市場區隔：依分銷通路分類

  • 銷售合作夥伴公司
  • 非政府組織（NGO）
  • 政府機構

第9章 市場區隔：依最終用戶分類

  • 兒童
  • 成人

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Pfizer Inc.
Product Code: SR112026A3133

The global pneumococcal vaccine market size was valued at USD 10.26 Billion in 2025 and is projected to reach USD 15.51 Billion by 2034, exhibiting a CAGR of 4.30% during the forecast period 2026-2034. Rising geriatric populations, expanding government immunization programs, growing burden of pneumococcal disease, and steady progress in next-generation conjugate vaccine platforms are driving the pneumococcal vaccine market growth. Pneumococcal conjugate vaccines lead at 71.6% share in 2025, while Prevnar 13 alone accounts for 48.7% of global product demand. North America dominates with 41.8% of global revenue in 2025.

Pneumococcal Vaccine Market Growth Factors:

Rising healthcare spending

High healthcare spending allows governments and private healthcare sectors to invest more in vaccination programs, leading to enhanced access and cost-effectiveness of pneumococcal vaccines, thereby increasing vaccination coverage rates across populations. In line with this, increasing healthcare spending often translates into better healthcare infrastructure, including vaccination clinics, distribution networks, and trained healthcare professionals. This infrastructure aids in the management and advocacy for pneumococcal vaccines, thus contributing to the growth of the market. Furthermore, high healthcare spending can lead to an increasing investment in research and development (R&D) activities by pharmaceutical companies, which encourages the enhancement of pneumococcal vaccines that work better, cover more serotypes or need fewer doses. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the health spending share of GDP is forecasted to grow from 17.3 percent in 2022 to 19.7 percent in 2032.

Growing aging population

Older people are more prone to pneumococcal infections, including pneumonia or invasive pneumococcal disease, due to weakened immune systems and underlying health conditions. This increasing vulnerability is leading to high utilization of pneumococcal vaccines to avoid such severe illnesses. Besides this, many governing agencies and healthcare organizations recommend pneumococcal vaccination for elderly populations as part of routine immunization schedules, which encourages healthcare providers and older adults to prioritize vaccination, thereby driving the pneumococcal vaccine demand. In addition, healthcare sectors prioritize preventive care strategies for aging populations to improve their health and minimize hospital readmissions. An article published on the website of the World Health Organization (WHO) shows that individuals aged over 60 are expected to double by 2050, reaching nearly 2.1 billion worldwide.

Increasing prevalence of sepsis

As per the content updated in 2024 on the website of the World Health Organization (WHO), almost 20 million of all estimated sepsis cases worldwide occurred in children under 5 years of age. Streptococcus pneumoniae, which causes pneumococcal infections, is one of the leading causes of sepsis, especially among children those with weakened immune systems. The rising occurrence of sepsis caused by pneumococcal infections underlines the importance of preventive approaches such as vaccination. In addition, vaccination against Streptococcus pneumoniae significantly reduces the risk of pneumococcal infections, including those that can lead to sepsis. By preventing pneumococcal diseases, vaccines help mitigate the overall burden of sepsis in healthcare settings. Apart from this, they reduce the overall burden of sepsis in care settings by preventing pneumococcal diseases. Furthermore, the administration of pneumococcal vaccines as a protective strategy against sepsis is increasing their sales. Prevention of sepsis morbidity and mortality through vaccination in public health intervention across the globe is supporting the market growth.

Pneumococcal Vaccine Market Segmentation:

The publisher provides an analysis of the pneumococcal vaccine industry trends in each segment, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on vaccine type, product type, distribution channel, and end user.

Breakup by Vaccine Type:

  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharide Vaccine

Pneumococcal conjugate vaccine accounts for the majority of the market share

The pneumococcal conjugate vaccine (PCV) is one of the most important products in the market because of its effectiveness in improving public health particularly among children below five years and elderly people. PCVs are aimed at offering protection against various serotypes of the streptococcus pneumoniae bacterium, which is known to cause severe and sometimes fatal conditions such as pneumonia, meningitis, and sepsis. PCVs have been proven to be effective in reducing the incidence of these diseases, which makes it possible to be incorporated in national immunization programs.

Breakup by Product Type:

  • Prevnar 13
  • Synflorix
  • Pneumovax 23

Prevnar 13 holds the largest share of the industry

Prevnar 13 is highly preferable due to its effectiveness in preventing infections caused by Streptococcus pneumoniae bacteria. This vaccine is particularly notable for its broad coverage against thirteen different strains of the bacteria. Its incorporation in national immunization programs worldwide is greatly impacting the cases of pneumococcal diseases especially in young children and older individuals. Moreover, its well-established clinical effectiveness and safety profile are ensuring its escalated utilization throughout the world, making it an essential pillar of modern healthcare systems in combating pneumococcal diseases.

Breakup by Distribution Channel:

  • Distribution Partner Companies
  • Non-Governmental Organizations (NGO)
  • Government Authorities

Non-governmental organizations (NGO) represent the leading market segment

Non-governmental organizations (NGO) contribute to market dynamics through various initiatives, including funding support for vaccination programs, raising awareness about the importance of pneumococcal immunization, and collaborating with governments and pharmaceutical companies to ensure affordability and availability of vaccines. NGOs also engage in R&D activities to improve vaccine efficacy and promote vaccination campaigns aimed at vulnerable populations such as children and the elderly. Their advocacy efforts also address socio-economic disparities in healthcare access, making pneumococcal vaccines more accessible and impactful worldwide.

Breakup by End User:

  • Pediatrics
  • Adults

Children, especially infants and toddlers, are highly vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and sepsis. Vaccination against pneumococcus bacteria is therefore recommended as part of routine childhood immunization schedules worldwide. The effectiveness of pneumococcal vaccines in preventing these infections is significantly reducing morbidity and mortality rates among children globally. Moreover, public health initiatives and immunization programs focused on pediatric populations are contributing to the pneumococcal vaccines market statistics.

As adults are aging, especially those over 65 or with underlying health conditions, they are becoming more vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and septicemia. Vaccination in adults helps reduce the risk of these infections and their associated complications, improving overall health outcomes and reducing healthcare costs. Additionally, adults often serve as carriers of pneumococcal bacteria, potentially spreading it to more vulnerable populations like children and the elderly people.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest pneumococcal vaccine market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pneumococcal vaccine.

As per the content updated in 2023 on the website of Centers for Medicare & Medicaid Services, U.S. health care spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. The increasing healthcare expenditure reflects a greater emphasis on improving patient outcomes and reducing overall healthcare costs through innovative technologies. Moreover, North America has stringent regulatory frameworks and strong government support for immunization programs that contribute significantly to the growth of the market. The prevalence of pneumococcal diseases in North America, coupled with increasing awareness among healthcare professionals and the general population about the benefits of vaccination, is also driving the demand for pneumococcal vaccines.

Competitive Landscape:

  • The market pneumococcal vaccine market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pneumococcal vaccine industry include Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd, and Walvax Biotechnology Co. Ltd.
  • Key players are investing in research and development (R&D) activities aimed at developing next-generation vaccine formulations. They are also expanding manufacturing capabilities to meet the growing global demand. Key players are also investing in clinical trials and studies to demonstrate efficacy and safety. They are also adopting innovative technologies for vaccine production and distribution. Many companies are implementing vaccination campaigns and educational programs to increase awareness and vaccine uptake. Key players are collaborating with other industry stakeholders, government agencies, healthcare organizations, and research institutions to expand their market reach and develop new products. For instance, in 2023, Vaxcyte, Inc. collaborated with Lonza for a new commercial manufacturing agreement. With this collaboration, Vaxcyte planned to expand its commercial manufacturing capacity for its PCV candidates.

Key Questions Answered in This Report

1. What was the size of the global pneumococcal vaccine market in 2025?

2. What is the expected growth rate of the global pneumococcal vaccine market during 2026-2034?

3. What has been the impact of COVID-19 on the global pneumococcal vaccine market?

4. What are the key factors driving the global pneumococcal vaccine market?

5. What is the breakup of the global pneumococcal vaccine market based on the vaccine type?

6. What is the breakup of the global pneumococcal vaccine market based on the product type?

7. What is the breakup of the global pneumococcal vaccine market based on the distribution channel?

8. What are the key regions in the global pneumococcal vaccine market?

9. Who are the key players/companies in the global pneumococcal vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pneumococcal Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Pneumococcal Conjugate Vaccine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pneumococcal Polysaccharide Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Prevnar 13
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Synflorix
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Pneumovax 23
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Distribution Partner Companies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-Governmental Organizations (NGO)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Government Authorities
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pediatrics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adults
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Pfizer Inc.

List of Figures

  • Figure 1: Global: Pneumococcal Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Pneumococcal Vaccine Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Pneumococcal Vaccine Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Pneumococcal Vaccine Market: Breakup by Vaccine Type (in %), 2025
  • Figure 5: Global: Pneumococcal Vaccine Market: Breakup by Product Type (in %), 2025
  • Figure 6: Global: Pneumococcal Vaccine Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Pneumococcal Vaccine Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Pneumococcal Vaccine Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Pneumococcal Vaccine (Prevnar 13) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Pneumococcal Vaccine (Prevnar 13) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Pneumococcal Vaccine (Synflorix) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Pneumococcal Vaccine (Synflorix) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Pneumococcal Vaccine (Pneumovax 23) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Pneumococcal Vaccine (Pneumovax 23) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Pneumococcal Vaccine (Government Authorities) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Pneumococcal Vaccine (Government Authorities) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Pneumococcal Vaccine (Pediatrics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Pneumococcal Vaccine (Pediatrics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Pneumococcal Vaccine (Adults) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Pneumococcal Vaccine (Adults) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: North America: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: North America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: United States: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: United States: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Canada: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Canada: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Asia-Pacific: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Asia-Pacific: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: China: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: China: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Japan: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Japan: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: India: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: India: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: South Korea: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: South Korea: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Australia: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Australia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Indonesia: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Indonesia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Others: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Europe: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Europe: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Germany: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Germany: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: France: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: France: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: United Kingdom: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: United Kingdom: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Italy: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Italy: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Spain: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Spain: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Russia: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Russia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Latin America: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Latin America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Brazil: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Brazil: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Mexico: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Mexico: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Middle East and Africa: Pneumococcal Vaccine Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Middle East and Africa: Pneumococcal Vaccine Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Middle East and Africa: Pneumococcal Vaccine Market: Breakup by Country (in %), 2025
  • Figure 78: Global: Pneumococcal Vaccine Industry: SWOT Analysis
  • Figure 79: Global: Pneumococcal Vaccine Industry: Value Chain Analysis
  • Figure 80: Global: Pneumococcal Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pneumococcal Vaccine Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Pneumococcal Vaccine Market Forecast: Breakup by Vaccine Type (in Million USD), 2026-2034
  • Table 3: Global: Pneumococcal Vaccine Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 4: Global: Pneumococcal Vaccine Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Pneumococcal Vaccine Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Pneumococcal Vaccine Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Pneumococcal Vaccine Market: Competitive Structure
  • Table 8: Global: Pneumococcal Vaccine Market: Key Players